Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds specifically-identified oligosaccharide structure
Patent
1994-02-18
1998-05-05
Loring, Susan A.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds specifically-identified oligosaccharide structure
4241411, 4241561, 435 7021, 4351722, 43524027, 5303881, 5303875, 5303871, 53038885, 530809, 5303873, A61K 39395, C12N 512, C12P 2108, C07K 1618
Patent
active
057470340
ABSTRACT:
Anti-B7-1 antibodies or other B7-1 ligands may be used to prevent or treat a T-cell-mediated immune system disease in a patient or to induce antigen-specific tolerance.
The anti-B7-1 antibodies may be used to cause T cell anergy, treat allograft transplant rejection, treat graft versus host disease, and prevent or treat rheumatoid arthritis. An immunosuppressive agent is co-administered with the antibody.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4689299 (1987-08-01), Insel et al.
patent: 4886796 (1989-12-01), Eichner et al.
patent: 4923872 (1990-05-01), Kostlan et al.
patent: 5068223 (1991-11-01), Lipsky et al.
patent: 5100899 (1992-03-01), Calne
Cosimi, et al., "Use of Monoclonal LAntibodies To T-Cell Subsets for Immunologic Monitoring and Treatment in Recipients of Renal Allografats," The New England Journal of Medicine, 305:308-313 (Aug. 6, 19881).
Kriegler, et al., "A Novel Form of TNF/Cachectin Is a Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF," Cell 53:45-53 (1988).
Co, M.S. et al., Nature, 351:501-502, 6 Jun. 1991.
Brostoff, J. et al., edit. Clinical Immunology, pub. Gower Medical, pp. 27.8 and 28.4-28.5, 1991.
Waldmann, T.A., Science, 252:1657-1662, Jun. 1991.
Harris, W.J. et al., TIBTECH, 11:42-44, Feb. 1993.
Winter, G. et al., TIPS, 14:139-143, May 1993.
Freeman, G.J. et al., Science, 262:909-911, Nov. 5, 1993.
Clark and Shu, "Association Between IL-6 and CD40 Signaling IL-6 Induces Phosphorylation of CD40 Receptors", J. Immunol, 145(5):1400-1406 (Sep. 1, 1990).
Sato et al., "Biological Effects in Vitro of Monoclonal Antibodies to Human Epidermal Growth Factor Receptors", Mol. Biol. Med., 1:511-529 (1983).
Aruffo and Seed, "Molecular cloning of a CD28 cDNA by high-efficiency COS cell expression system," Proc. Natl. Acad. Sci. (USA), 84:8573-8577 (Dec. 1987).
Aruffo et al., "The Lymphocyte Glycoprotein CD6 Contains a Repeated Domain Structure Characteristic of a New Family of Cell Surface and Secreted Proteins," J. Exp. Med., 174:949-952 (Oct. 1991).
Barneveld et al., "Monoclonal Antibodies against Human .beta.-Glucocerebrosidase," Eur. J. Biochem., 134:585-589 (1983).
Boussiotis et al., "Activated human B lymphocyte express three CTLA-4 counterreceptors that contimulate T-cell activation," Proc. Natl. Acad. Sci. (USA), 90:11059-11063 (Dec. 1993).
Cafiso et al., "Preparation of Unilamellar Lipid Vesicles at 37.degree. C. by Vaporization Methods," Biochem. Biophys. Acta, 649:129-132 (1981).
de Boer et al., "Functional characterization of a novel anti-B7 monoclonal antibody," Eur. J. Immunol, 22:3071-3075 (1992).
de Boer et al., "Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins," J. Immunol. Methods, 152:15-23 (1992).
Dharakul et al., "Immunization with Baculovirus-Expressed Recombinant Rotavirus Proteins VP1, VP4, VP6, and VP7 Induces CD8.sup.+ T Lymphocytes that Mediate Clearance of Chronic Rotavirus Infection in SCID Mice," J. Virol., 65(11):5928-5932 (Nov. 1991).
DiSanto et al., "Generation of anti-human CD8.beta.-specific antibodies using transfectants expressing mixed-species CD8 heterodimers," J. Immunol. Methods, 141:123-131 (1991).
Fleming et al., "In Situ Expression of a B7-Like Adhesion Molecule on Keratinocytes from Human Epidermis," J. Investigative Dermatology, 101(5):754-758 (Nov. 1993).
Fraser et al., "Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28," Science, 251:313-316 (Jan. 18, 1991).
Freedman et al., "B7, A B Cell-Restricted Antigen that Identifies Preactivated B Cells," J. Immunol., 139(10):3260-3267 (Nov. 15, 1987).
Freeman et al., "B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells," J. Immunol, 143(8):2714-2722 (Oct. 15, 1989).
Freedman et al., "Selective Induction of B7/BB-1 on Interferon-.gamma. Stimulated Monocytes," Cell. Immunol., 137:429-437 (1991).
Gabizon et al., "Liposomes as In Vivo Carriers of Adriamycin: Reduced Cardiac Uptake and Preserved Antitumor Activity in Mice," Cancer Research, 42:4734-4739 (Nov. 1982).
Go et al., "Anergized T Cell Clones Retain Their Cytolytic Ability," J. Immunol, 150(2):367-376 (Jan. 15, 1993).
Golub, Immunology A Synthesis, pp. 19-20, Sinauer Associates, Inc. (1987).
Haffar et al., "Costimulation of T-Cell activation and virus production by B7 antigen on activated CD4.sup.+ T cells from human immunodeficiency virus type 1-infected donors," Proc. Natl. Acad. Sci. USA, 90:11094-11098 (Dec. 1993).
Harding et al., "CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," Nature, 356:607609 (Apr. 16, 1992).
Harper et al., "CTLA-4 and CD28 Activated Lymphocyte Molecules are Closely Related in Both Mouse and Human as to Sequence, Message Expression, Gene Structure, and Chromosomal Location," J. ImmunoL, 147(3):1037-1044 (Aug. 1, 1991).
Gimmi et al., "B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2," Proc. Natl. Acad. Sci. (USA) 88:6575 (1991).
Hathcock et al., "Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation," Science, 262:905-911 (Nov. 5, 1993).
Hawrylowicz and Unanue, "Regulation of Antigen-Presentation-I," J. Immunol., 141(12):4083-4088 (Dec. 15, 1988).
Jenkins and Schwartz, "Antigen Presentation by Chemically Modified Splenocytes Induces Antigen-Specific T Cell Unresponsiveness in Vitro and in Vivo," J. Exp. Med., 165:302-319 (Feb. 1987).
Jenkins et al., "Allogeneic Non-T Spleen Cells Restore the Responsiveness of Normal T Cell Clones Stimulated with Antigen and Chemically Modified Antigen-Presenting Cells," J. Immunol., 140(10):3324-3330 (May 15, 1988).
Jenkins et al., "Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones," Proc. Natl. Acad. Sci. (USA), 84:5409-5413 (Aug. 1987).
June et al., "Evidence for the Involvement of Three Distinct Signals in the Induction of IL-2 Gene Expression in Human T Lymphocytes," J. Immunol., 143(1):153-161 (Jul. 1, 1989).
June et al., "Role of the CD28 receptor in T-cell activation," Innun. Today, 11(6):211-216 (1990).
June et al., "T-Cell Proliferation Involving the CD28 Pathway is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression," Mol. Cell. Biol., 7(12):4472-4481 (Dec. 1987).
Knauf et al., Relationship of Effective Molecular Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-soluble Polymers, J. Bio. Chem., 263(29):15064-15070 (Oct. 15, 1988).
Kohler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, 256:495-496 (Aug. 7, 1975).
Kosco-Vilbois et al., "Follicular Dendritic Cells Help Resting B Cells to Become Effective Antigen-presenting Cells: Induction of B7/BB1 and Upregulation of Major Histocompatibility Complex Class II Molecules," J. Exp. Med., 178:2055-2066 (Dec. 1993).
Kubota et al., "Identification and Gene Cloning of a New Phosphatidylinositol-Linked Antigen Expressed on Mature Lymphocytes," J. Immunol., 145(11):3924-3931 (Dec. 1, 1990).
Lenschow et al., "Expression and functional significance of an additional ligand for CTLA-4," Proc. Natl. Acad. Sci USA, 90:11054-11058 (1993).
Lenschow et al., "Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA41g," Science, 257:789-792 (Aug. 7, 1992).
Lin et al., "Long-Term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA4Ig Plus Donor-specific Transfusion," J. Exp. Med., 178:1801-1086 (Nov. 1983).
Linsley et al., "CTLA-4 is a Second Receptor for the B Cell Activation Antigen B7," J. Exp. Med., 174:561-569 (Sep. 1991).
Linsley et al., "Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule," Science, 257.792-795 (Aug. 7, 1992).
Mueller et al., "Clonal Expansion Versus Functional Clonal Inactivation: A Costimulatory Signalling Pathway
Conroy Leah B.
de Boer Mark
Blackburn Robert P.
Chiron Corporation
Loring Susan A.
Pochopien Donald J.
Savereide Paul B.
LandOfFree
Methods and materials for the induction of T cell anergy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and materials for the induction of T cell anergy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and materials for the induction of T cell anergy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-51103